Real-life EValuation Of high dose RosUvastatin in high risk patients after TitraTION - REVORUTION

Study identifier:NIS-CKR-CRE-2007/6

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An observational, non-interventional, multi-center study to evaluate efficacy and tolerability of high dose rosuvastatin in High Risk Patients after titration

Medical condition

Hypercholesterolemia

Phase

Healthy volunteers

Study drug

Sex

All

Actual Enrollment

1482

Study type

Observational

Age

18 Years +

Date

Study Start Date: 01 May 2007

Primary Completion Date: 01 Apr 2008

Study Completion Date: 01 Apr 2008

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Seoul, Songpa-gu, Republic of Korea

Location

Research Site

Seoul, Jongro-gu, Republic of Korea

Location

Research Site

Seoul, Kangnam-gu, Republic of Korea

Arms	Assigned Interventions

"There is no result for the study"

Documents available

NIS-CKR-CRE-2007/6 CSR Synopsis
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Korea Clinical Study

82-2-2188-2142

myunghwan.chi@astrazeneca.com

Investigators

Principal Investigator

Hyunah Caroline Choi

AstraZeneca Korea

Real-life EValuation Of high dose RosUvastatin in high risk patients after TitraTION - REVORUTION

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Research Site

Research Site

Research Site

Documents available

NIS-CKR-CRE-2007/6 CSR Synopsis

Trial Results Summaries

Contacts

Contact

Investigators

Principal Investigator